BridgeBio Pharma Inc.

48.46-0.2700-0.55%Vol 1.09M1Y Perf 29.93%
Sep 15th, 2021 16:00 DELAYED
BID48.43 ASK48.46
Open48.96 Previous Close48.73
Pre-Market- After-Market-
 - -%  - -
Target Price
79.25 
Analyst Rating
Strong Buy 1.11
Potential %
63.54 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★     51.03
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
32.87 
Earnings Rating
Market Cap7.26B 
Earnings Date
4th Nov 2021
Alpha0.02 Standard Deviation0.17
Beta0.73 

Today's Price Range

47.6949.48

52W Range

36.2073.50

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-4.74%
1 Month
-2.06%
3 Months
-23.30%
6 Months
-28.79%
1 Year
29.93%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
BBIO48.46-0.2700-0.55
AAPL149.030.91000.61
GOOG2 904.1236.00001.26
MSFT304.825.03001.68
XOM56.421.84003.37
WFC46.640.59001.28
JNJ165.420.62000.38
FB373.92-2.6100-0.69
GE102.161.78001.77
JPM158.161.09000.69
Earnings HistoryEstimateReportedSurprise %
Q02 2021-0.93-0.6629.03
Q01 2021-0.87-1.18-35.63
Q04 2020-0.86-1.01-17.44
Q03 2020-0.97-0.98-1.03
Q02 2020-0.79-1.03-30.38
Q01 2020-0.69-0.78-13.04
Q04 2019-0.70-0.6211.43
Q03 2019-0.55-0.517.27
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date4th Nov 2021
Estimated EPS Next Report-0.88
Estimates Count6
EPS Growth Next 5 Years %-
Volume Overview
Volume1.09M
Shares Outstanding149.77M
Shares Float82.24M
Trades Count10.48K
Dollar Volume130.81M
Avg. Volume893.33K
Avg. Weekly Volume853.61K
Avg. Monthly Volume732.19K
Avg. Quarterly Volume847.21K

BridgeBio Pharma Inc. (NASDAQ: BBIO) stock closed at 48.46 per share at the end of the most recent trading day (a -0.55% change compared to the prior day closing price) with a volume of 1.10M shares and market capitalization of 7.26B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 396 people. BridgeBio Pharma Inc. CEO is Neil Kumar.

The one-year performance of BridgeBio Pharma Inc. stock is 29.93%, while year-to-date (YTD) performance is -31.85%. BBIO stock has a five-year performance of %. Its 52-week range is between 36.2 and 73.5, which gives BBIO stock a 52-week price range ratio of 32.87%

BridgeBio Pharma Inc. currently has a PE ratio of -13.10, a price-to-book (PB) ratio of 123.68, a price-to-sale (PS) ratio of 121.54, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -48.63%, a ROC of -63.99% and a ROE of 538.78%. The company’s profit margin is -%, its EBITDA margin is -782.30%, and its revenue ttm is $62.74 Million , which makes it $0.42 revenue per share.

Of the last four earnings reports from BridgeBio Pharma Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.88 for the next earnings report. BridgeBio Pharma Inc.’s next earnings report date is 04th Nov 2021.

The consensus rating of Wall Street analysts for BridgeBio Pharma Inc. is Strong Buy (1.11), with a target price of $79.25, which is +63.54% compared to the current price. The earnings rating for BridgeBio Pharma Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

BridgeBio Pharma Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

BridgeBio Pharma Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 9.75, ATR14 : 2.01, CCI20 : -111.40, Chaikin Money Flow : -0.03, MACD : -0.94, Money Flow Index : 48.09, ROC : -4.00, RSI : 39.58, STOCH (14,3) : 16.38, STOCH RSI : 0.00, UO : 40.66, Williams %R : -83.62), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of BridgeBio Pharma Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
8 (88.89 %)
7 (87.50 %)
6 (85.71 %)
Moderate Buy
1 (11.11 %)
1 (12.50 %)
1 (14.29 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.11
Strong Buy
1.13
Strong Buy
1.14

BridgeBio Pharma Inc.

BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.

CEO: Neil Kumar

Telephone: +1 650 391-9740

Address: 421 Kipling Street, Palo Alto 94301, CA, US

Number of employees: 396

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

100%0%

Bearish Bullish

54%46%

Bearish Bullish

66%34%

News

Stocktwits